Previous 10 | Next 10 |
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO...
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet ...
Verrica Pharmaceuticals press release (NASDAQ:VRCA): Q4 GAAP EPS of -$0.35 beats by $0.14. As of December 31, 2021, Verrica had aggregate cash, cash equivalents, and marketable securities of $70.4 million. For further details see: Verrica Pharmaceuticals GAAP EPS of -$0.35 beats by $0.1...
NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarter of 2022 WEST CHESTER, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmace...
WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO,...
Calliditas Therapeutics (NASDAQ:CALT) +67%. Recursion Pharmaceuticals (NASDAQ:RXRX) +10%. Verrica Pharmaceuticals (NASDAQ:VRCA) +9%. Qorvo (NASDAQ:QRVO) +6%. Sharecare (NASDAQ:SHCR) +5%. Blue Bird (NASDAQ:BLBD) -10%. Freshworks (NASDAQ:FRSH) -4%. Nutanix (NASDAQ:NTNX) -4%. Cumberland Pharmace...
The FDA has accepted a resubmitted NDA from Verrica Pharmaceuticals (NASDAQ:VRCA) for VP-102 for the treatment of the skin disease molluscum contagiosum. The PDUFA date is May 24, 2022. The FDA declined to approve VP-102 in September due to a facility manufacturing issue. For further detail...
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration...
Verrica Pharmaceuticals (NASDAQ:VRCA) says that FDA has accepted its Investigational New Drug Application (“IND”) for LTX-315 as a potential treatment for basal cell carcinoma. An oncolytic peptide immunotherapy designed for direct administration into tumor tissue to trigge...
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST CHESTER, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals I...
News, Short Squeeze, Breakout and More Instantly...
Verrica Pharmaceuticals Inc. Company Name:
VRCA Stock Symbol:
NASDAQ Market:
Verrica Pharmaceuticals Inc. Website:
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 202...
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Pr...
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a cost and time to market standpoint; funding structure is expected to have a min...